27.81 USD
-0.23 (-0.82%)
27.81 USD
0 (0%)
Taking everything into account, ALKS scores 6 out of 10 in our fundamental rating. ALKS was compared to 529 industry peers in the Biotechnology industry. ALKS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ALKS is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
ALKS had positive earnings in the past year.
ALKS had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ALKS reported negative net income in multiple years.
Each year in the past 5 years ALKS had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 14.57%, ALKS belongs to the top of the industry, outperforming 95.09% of the companies in the same industry.
The Return On Equity of ALKS (19.58%) is better than 96.03% of its industry peers.
The Return On Invested Capital of ALKS (16.22%) is better than 96.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.57% | ||
| ROE | 19.58% | ||
| ROIC | 16.22% |
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALKS has a Profit Margin of 22.30%. This is amongst the best in the industry. ALKS outperforms 94.33% of its industry peers.
The Operating Margin of ALKS (23.59%) is better than 95.65% of its industry peers.
ALKS has a better Gross Margin (86.04%) than 88.47% of its industry peers.
In the last couple of years the Gross Margin of ALKS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 22.3% | ||
| GM | 86.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
2. Health
2.1 Basic Checks
ALKS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, ALKS has less shares outstanding
ALKS has more shares outstanding than it did 5 years ago.
ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 5.97 indicates that ALKS is not in any danger for bankruptcy at the moment.
ALKS has a better Altman-Z score (5.97) than 75.05% of its industry peers.
ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.97 |
ROIC/WACC2.11
WACC7.69%
2.3 Liquidity
A Current Ratio of 3.67 indicates that ALKS has no problem at all paying its short term obligations.
ALKS's Current ratio of 3.67 is in line compared to the rest of the industry. ALKS outperforms 43.86% of its industry peers.
ALKS has a Quick Ratio of 3.27. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.27, ALKS perfoms like the industry average, outperforming 40.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.67 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.71% over the past year.
ALKS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 32.50% yearly.
ALKS shows a small growth in Revenue. In the last year, the Revenue has grown by 1.08%.
ALKS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.87% yearly.
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
3.2 Future
The Earnings Per Share is expected to decrease by -1.55% on average over the next years.
Based on estimates for the next years, ALKS will show a small growth in Revenue. The Revenue will grow by 7.72% on average per year.
EPS Next Y-48.04%
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
EPS Next 5Y-1.55%
Revenue Next Year-2.41%
Revenue Next 2Y10.1%
Revenue Next 3Y6.85%
Revenue Next 5Y7.72%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 11.21, which indicates a very decent valuation of ALKS.
Based on the Price/Earnings ratio, ALKS is valued cheaper than 97.16% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.26, ALKS is valued rather cheaply.
ALKS is valuated rather expensively with a Price/Forward Earnings ratio of 18.26.
Based on the Price/Forward Earnings ratio, ALKS is valued cheaper than 94.71% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ALKS to the average of the S&P500 Index (23.68), we can say ALKS is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.21 | ||
| Fwd PE | 18.26 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALKS is valued cheaper than 97.73% of the companies in the same industry.
ALKS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ALKS is cheaper than 98.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.35 | ||
| EV/EBITDA | 7.67 |
4.3 Compensation for Growth
The decent profitability rating of ALKS may justify a higher PE ratio.
A cheap valuation may be justified as ALKS's earnings are expected to decrease with -19.20% in the coming years.
PEG (NY)N/A
PEG (5Y)0.34
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
5. Dividend
5.1 Amount
ALKS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
27.81
-0.23 (-0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.69%
Inst Owner Change8.97%
Ins Owners1.48%
Ins Owner Change-0.34%
Market Cap4.59B
Revenue(TTM)1.52B
Net Income(TTM)339.32M
Analysts80.87
Price Target44.75 (60.91%)
Short Float %11.63%
Short Ratio7.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.1%
Min EPS beat(2)59.84%
Max EPS beat(2)72.36%
EPS beat(4)4
Avg EPS beat(4)43.68%
Min EPS beat(4)12.02%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)10.27%
EPS beat(12)8
Avg EPS beat(12)42.89%
EPS beat(16)11
Avg EPS beat(16)151.46%
Revenue beat(2)2
Avg Revenue beat(2)10.32%
Min Revenue beat(2)8.51%
Max Revenue beat(2)12.13%
Revenue beat(4)3
Avg Revenue beat(4)7.62%
Min Revenue beat(4)-1.19%
Max Revenue beat(4)12.13%
Revenue beat(8)4
Avg Revenue beat(8)3.11%
Revenue beat(12)7
Avg Revenue beat(12)3.8%
Revenue beat(16)10
Avg Revenue beat(16)3.09%
PT rev (1m)0.32%
PT rev (3m)4.46%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)1.27%
EPS NY rev (1m)-0.04%
EPS NY rev (3m)17.54%
Revenue NQ rev (1m)0.18%
Revenue NQ rev (3m)3.41%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)3.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.21 | ||
| Fwd PE | 18.26 | ||
| P/S | 3.02 | ||
| P/FCF | 9.35 | ||
| P/OCF | 8.49 | ||
| P/B | 2.65 | ||
| P/tB | 2.78 | ||
| EV/EBITDA | 7.67 |
EPS(TTM)2.48
EY8.92%
EPS(NY)1.52
Fwd EY5.48%
FCF(TTM)2.98
FCFY10.7%
OCF(TTM)3.27
OCFY11.77%
SpS9.21
BVpS10.5
TBVpS9.99
PEG (NY)N/A
PEG (5Y)0.34
Graham Number24.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.57% | ||
| ROE | 19.58% | ||
| ROCE | 19.34% | ||
| ROIC | 16.22% | ||
| ROICexc | 40.45% | ||
| ROICexgc | 45.58% | ||
| OM | 23.59% | ||
| PM (TTM) | 22.3% | ||
| GM | 86.04% | ||
| FCFM | 32.29% |
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 163.07% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 138.93% | ||
| Profit Quality | 144.77% | ||
| Current Ratio | 3.67 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 5.97 |
F-Score6
WACC7.69%
ROIC/WACC2.11
Cap/Depr(3y)76.88%
Cap/Depr(5y)63.55%
Cap/Sales(3y)2.83%
Cap/Sales(5y)2.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
EPS Next Y-48.04%
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
EPS Next 5Y-1.55%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
Revenue Next Year-2.41%
Revenue Next 2Y10.1%
Revenue Next 3Y6.85%
Revenue Next 5Y7.72%
EBIT growth 1Y-17.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.47%
EBIT Next 3Y5.58%
EBIT Next 5Y14.79%
FCF growth 1Y93.4%
FCF growth 3Y76.56%
FCF growth 5YN/A
OCF growth 1Y83.22%
OCF growth 3Y62.84%
OCF growth 5Y43.53%
ALKERMES PLC / ALKS FAQ
What is the fundamental rating for ALKS stock?
ChartMill assigns a fundamental rating of 6 / 10 to ALKS.
What is the valuation status for ALKS stock?
ChartMill assigns a valuation rating of 6 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.
Can you provide the profitability details for ALKERMES PLC?
ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.
What is the valuation of ALKERMES PLC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ALKERMES PLC (ALKS) is 11.21 and the Price/Book (PB) ratio is 2.65.
What is the expected EPS growth for ALKERMES PLC (ALKS) stock?
The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -48.04% in the next year.